Healthcare / Medical Instruments & SuppliesTokyo
$484.00
-4.00 (-0.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 18%
FCF escenarios
weak_data · normalized FCF $2.2B · quality 25.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$14.6B
P/E
12.9x
↓EV/EBITDA
6.7x
↓ROE
6.0%
↑Gross Margin
44.0%
↓Debt/Equity
1.46
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.8%
FCF CAGR
—
FCF margin
-5.2%
FCF / Net income
-1.60x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $33.23B · net income $1.09B · FCF $-1.74B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $33.23B | $33.23B | $32.40B | $30.59B | $28.84B |
| Net Income | $1.09B | $1.09B | $1.96B | $-316.1M | $1.15B |
| EBITDA | $5.05B | $5.05B | $5.12B | $2.83B | $4.45B |
| EPS | 36.10 | 36.10 | 77.40 | -12.63 | 46.09 |
| Gross Margin | 44.0% | 44.0% | 43.8% | 38.0% | 41.7% |
| Operating Margin | 4.7% | 4.7% | 6.3% | 2.1% | 4.1% |
| Net Margin | 3.3% | 3.3% | 6.1% | -1.0% | 4.0% |
| Balance Sheet | |||||
| Debt/Equity | 1.46 | 1.46 | 1.40 | 1.77 | 1.80 |
| Current Ratio | 0.79 | 0.79 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.74B | $-1.74B | $2.19B | $2.79B | $2.15B |
| Returns | |||||
| ROE | 6.0% | 6.0% | 11.3% | -2.7% | 9.4% |
| Valuation | |||||
| P/E | 12.90 | 12.90 | 8.01 | — | 11.04 |
| EV/EBITDA | 6.71 | 6.71 | 5.88 | 10.45 | 6.96 |
| P/B | 0.81 | 0.81 | 0.91 | 1.14 | 1.04 |
| Growth & Yield | |||||
| Revenue Growth | 2.6% | 2.6% | 5.9% | 6.1% | — |
| EPS Growth | -53.4% | -53.4% | 712.8% | -127.4% | — |
| Dividend Yield | 3.1% | 3.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
6.0%
EPS terminal req.
$42.95
Spread vs growth
-59.3%
5Y implied EPS CAGR
7.6%
EPS terminal req.
$51.97
Spread vs growth
-60.9%
10Y implied EPS CAGR
8.8%
EPS terminal req.
$83.69
Spread vs growth
-62.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+11.8%
Start / end P/E
5.7x → 13.4x
EPS bridge
77.40 → 36.10
Residual
-71.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.